Cover Image
Market Research Report
Product code
1017907

Clinical Trial Supplies Market by Services (Manufacturing, Packaging, Logistics, Distribution), Phases (I to IV), Type (Small molecule, Biologics, Medical Devices) Therapeutic Areas (Oncology, CNS, CVD, Infectious, Immunology) - Global Forecast 2026

Published: | MarketsandMarkets | 233 Pages | Delivery time: 1-2 business days

Price

Back to Top
Clinical Trial Supplies Market by Services (Manufacturing, Packaging, Logistics, Distribution), Phases (I to IV), Type (Small molecule, Biologics, Medical Devices) Therapeutic Areas (Oncology, CNS, CVD, Infectious, Immunology) - Global Forecast 2026
Published: July 7, 2021
MarketsandMarkets
Content info: 233 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

The global clinical trial supplies market is projected to reach USD 2.9 billion by 2026 from USD 1.9 billion in 2021, at a CAGR of 8.5% during the forecast period of 2021 to 2026. Market growth is largely driven by the increasing R&D expenditure in pharmaceutical and biopharmaceutical companies and the growing number of clinical trials conducted globally. However, the increasing cost of drug development and clinical trials is expected to restrain the growth of this market during the forecast period.

"The logistics and distributionsegment accounted for the highest growth rate in the clinical trial supplies market, byservice, during the forecast period"

In 2020, the logistics & distribution services segment accounted for the largest share (26.3%) of the clinical trial supplies market, mainly due to the globalization of clinical trials, the increasing number of trials involving temperature-sensitive products, the highly regulated nature of the market, and expertise of supply companies in terms of therapeutic areas and geographical reach. The growth of the fastest-growing segment was attributed to the increasing number of clinical trials conducted and the decentralization of the trials across the globe.

"Oncologysegment accounted for the largest share of the therapeutic area segment"

Based on the therapeutic area, the clinical trial supplies market is segmented into oncology, CNS & mental disorders, cardiovascular diseases, digestive disorders, infectious diseases, metabolic disorders, immunology, blood disorders, and other therapeutic areas (respiratory disorders, dermatological disorders, rare diseases, ENT diseases, Nephrology) Oncology is the largest segment in this market owing to the high and growing number of research studies on cancer therapeutics and the increasing number of companies focusing on bringing innovative cancer drugs into the market. Also, the high incidence and prevalence of cancer, healthcare systems across the globe are focusing on reducing the burden of cancer by adopting innovative diagnostic and therapeutic approaches is a driver. In this scenario, effective drugs might witness widespread adoption in major markets such as the US, Europe, and the Asia Pacific. Considering these factors, many pharmaceutical companies are making significant investments in the development of innovative cancer drugs.

"Asia Pacific: The fastest-growing regionin theclinical trial suppliesmarket"

Theclinical trial suppliesmarket is segmented into North America, Europe, Asia Pacific,RoWThe APAC market, on the other hand, is expected to be the fastest-growing regional segment during the forecast period owing to increasing investments and expansions by big pharma companies in countries such as China, India, and South Korea.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 80%and Demand Side 20%
  • By Designation: C-level - 25%, D-level - 20%, and Others - 55%
  • By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%

Lists of Companies Profiled in the Report:

  • Thermo Fisher (US)
  • Catalent, Inc. (US)
  • Parexel (US)
  • Eurofins (France)
  • UDG Healthcare (Ireland)
  • Piramal Pharma Solutions (India)
  • Almac Group (UK)
  • PCI Pharma Services (US)
  • PRA Health Sciences (US)
  • Biocair (UK), Eurofins (France)
  • Marken (US)
  • Infosys (India)
  • Liveo Research (India)
  • Capsugel (a Lonza Group company) (Switzerland)
  • SIRO Clinpharm (India)
  • KLIFO A/S (Denmark)
  • Clinigen (UK)
  • Ancillare (US)
  • N-SIDE (Belgium)
  • ADAllen (UK)
  • Rubicon (India)
  • Durbin (UK)
  • Recipharm (Sweden)
  • Seveillar (India)
  • Myonex (India)

Research Coverage:

This report provides a detailed picture of theclinical trial supplies market. It aims at estimating the size and future growth potential of the market across different segments such as the service, end user, phases, therapeutic areas, type and region. The report also includes an in-depth competitive analysis ofthe key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial supplies marketand its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers,restraints,trends,and opportunities.

Table of Contents
Product Code: PH 3772

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 BREAKDOWN OF PRIMARIES: CLINICAL TRIAL SUPPLIES MARKET
    • 2.1.3 MARKET DATA ESTIMATION & TRIANGULATION
    • FIGURE 3 DATA TRIANGULATION METHODOLOGY
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 4 MARKET SIZE ESTIMATION APPROACH: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
    • FIGURE 5 MARKET SIZE ESTIMATION APPROACH: PARENT MARKET (TOP-DOWN APPROACH)
    • FIGURE 6 CLINICAL TRIAL SUPPLIES MARKET: FINAL MARKET SIZE (USD BILLION)
  • 2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
    • FIGURE 7 GROWTH RATE ASSUMPTION BASED ON MARKET DYNAMICS
    • FIGURE 8 FINAL CAGR PROJECTIONS (2021-2026)
  • 2.4 INSIGHTS FROM PRIMARIES
    • FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

    • FIGURE 10 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE, 2020 VS. 2026
    • FIGURE 11 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY SERVICE, 2020
    • FIGURE 12 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021 VS. 2026
    • FIGURE 13 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY THERAPEUTIC AREA, 2020
    • FIGURE 14 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY END USER, 2020
    • FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE CLINICAL TRIAL SUPPLIES MARKET

4 PREMIUM INSIGHTS

  • 4.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW
    • FIGURE 16 INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE & COUNTRY (2020)
    • FIGURE 17 SMALL-MOLECULE DRUGS ACCOUNTED FOR THE LARGEST SHARE OF THE CLINICAL TRIAL SUPPLIES MARKET IN NORTH AMERICA
  • 4.3 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 18 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE CLINICAL TRIAL SUPPLIES MARKET FROM 2021 TO 2026

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 CLINICAL TRIAL SUPPLIES MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • 5.3 IMPACT ANALYSIS
    • 5.3.1 DRIVERS
      • 5.3.1.1 Increasing R&D expenditure of pharmaceutical and biopharmaceutical companies
    • TABLE 2 R&D EXPENDITURE OF LEADING PHARMACEUTICAL COMPANIES IN 2019
    • FIGURE 20 NUMBER OF PHARMA COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010-2020)
    • FIGURE 21 GLOBAL R&D SPENDING (2016-2020)
      • 5.3.1.2 Increasing number of registered clinical trials
    • FIGURE 22 NUMBER OF CLINICAL TRIALS IN THE LAST 10 YEARS
      • 5.3.1.3 Increasing decentralization of clinical trials
    • 5.3.2 RESTRAINTS
      • 5.3.2.1 High cost of drug development
    • 5.3.3 OPPORTUNITIES
      • 5.3.3.1 Emerging markets
  • 5.4 RANGES/SCENARIOS
    • FIGURE 23 DEPENDING ON HOW UNCERTAINTIES UNFOLD, WE SEE A SPECTRUM OF SCENARIOS FOR THE CLINICAL TRIAL SUPPLIES MARKET
  • 5.5 COVID-19 IMPACT ANALYSIS
    • FIGURE 24 NUMBER OF CLINICAL TRIALS, BY PHASE (2020-2021)
    • FIGURE 25 NUMBER OF CLINICAL TRIALS, BY COUNTRY
  • 5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 26 PRE-COVID-19 VS. POST-COVID-19 SCENARIO
  • 5.7 VALUE CHAIN ANALYSIS
    • FIGURE 27 VALUE CHAIN ANALYSIS OF THE CLINICAL TRIAL SUPPLIES MARKET
  • 5.8 ECOSYSTEM/MARKET MAP
  • 5.9 SUPPLY CHAIN
  • 5.10 PORTER'S FIVE FORCES ANALYSIS
    • 5.10.1 PORTER'S 5 FORCES IMPACT ON THE CLINICAL TRIAL SUPPLIES MARKET
      • 5.10.1.1 Threat from new entrants
      • 5.10.1.2 Threat from substitutes
      • 5.10.1.3 Bargaining power of suppliers
      • 5.10.1.4 Bargaining power of buyers
      • 5.10.1.5 Degree of competition
  • 5.11 REGULATORY LANDSCAPE
    • 5.11.1 INTRODUCTION

6 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE

  • 6.1 INTRODUCTION
    • TABLE 3 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
  • 6.2 LOGISTICS & DISTRIBUTION
    • 6.2.1 INCREASING COMPLEXITY, EVOLVING TREATMENT PROTOCOLS, TECHNOLOGICAL ADVANCEMENTS, AND DATA SECURITY CHALLENGES TO DRIVE THE DEMAND FOR LOGISTICS & DISTRIBUTION SERVICES
    • TABLE 4 CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 5 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 6 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 7 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.3 STORAGE & RETENTION
    • 6.3.1 GROWING DEMAND FOR DIRECT-TO-PATIENT AND DIRECT-TO-SITE SERVICES TO DRIVE GROWTH IN THE STORAGE & RETENTION SERVICES MARKET SEGMENT
    • TABLE 8 CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 9 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 10 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 11 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.4 PACKAGING, LABELING, AND BLINDING
    • 6.4.1 RISING DEMAND FOR ADVANCED PACKAGING TO DRIVE THIS MARKET SEGMENT.
    • TABLE 12 CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 13 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 14 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 15 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.5 MANUFACTURING
    • 6.5.1 GROWING FOCUS OF COMPANIES ON INCREASING THEIR MANUFACTURING CAPACITIES TO DRIVE MARKET GROWTH
    • TABLE 16 CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 17 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 18 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 19 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.6 COMPARATOR SOURCING
    • 6.6.1 INTENSE MARKET COMPETITION, REGULATORY PRESSURE, INCREASING NUMBER OF CO-THERAPIES, AND THE RISING NUMBER OF CLINICAL TRIALS IN EMERGING COUNTRIES TO DRIVE GROWTH IN THIS SEGMENT
    • TABLE 20 CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 21 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 22 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 23 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.7 OTHER SERVICES
    • TABLE 24 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 25 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 26 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 27 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2019-2026 (USD MILLION)

7 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE

  • 7.1 INTRODUCTION
    • TABLE 28 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
  • 7.2 PHASE III
    • 7.2.1 SINCE PHASE III TRIALS INVOLVE A LARGE PATIENT POPULATION, THE DEMAND FOR OUTSOURCING OF CLINICAL TRIAL SUPPLIES IS HIGH IN THIS PHASE
    • TABLE 29 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 30 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 31 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 32 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.3 PHASE II
    • 7.3.1 PHASE II CLINICAL TRIALS HELP IN UNDERSTANDING THE EFFECTIVENESS OF THE DRUG AND FURTHER EVALUATING ITS SAFETY-A KEY FACTOR DRIVING MARKET GROWTH
    • TABLE 33 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 34 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 35 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 36 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.4 PHASE I
    • 7.4.1 QUALITY OF CLINICAL TRIAL SUPPLIES AND LOGISTICS PLAY A VITAL ROLE IN PHASE I CLINICAL TRIALS
    • TABLE 37 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 38 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 39 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 40 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.5 PHASE IV
    • 7.5.1 THESE STUDIES PRIMARILY ALLOW RESEARCHERS TO FIND AND OBSERVE THE LONG-TERM EFFECTS OF A PARTICULAR DRUG IN A CONSIDERABLY LARGER POOL OF PATIENTS-A KEY FACTOR DRIVING MARKET GROWTH
    • TABLE 41 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 42 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 43 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 44 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.6 BA/BE STUDIES
    • 7.6.1 INCREASING PATENT EXPIRATION TO INCREASE THE DEMAND FOR BA/BE STUDIES
    • TABLE 45 CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 46 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 47 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 48 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2019-2026 (USD MILLION)

8 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE

  • 8.1 INTRODUCTION
    • TABLE 49 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
  • 8.2 SMALL-MOLECULE DRUGS
    • 8.2.1 LOW COST OF DEVELOPING SMALL-MOLECULE DRUGS TO DRIVE MARKET GROWTH
    • TABLE 50 CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 51 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 52 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 53 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.3 BIOLOGIC DRUGS
    • 8.3.1 BIOLOGIC DRUGS HAVE A RELATIVELY LOW RATE OF ATTRITION COMPARED TO SMALL-MOLECULE DRUGS-A KEY FACTOR DRIVING MARKET GROWTH
    • TABLE 54 CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 55 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 56 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 57 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.4 MEDICAL DEVICES
    • 8.4.1 INCREASING NUMBER OF TRIALS FOR MEDICAL DEVICES TO DRIVE MARKET GROWTH
    • TABLE 58 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 59 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 60 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 61 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2019-2026 (USD MILLION)

9 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA

  • 9.1 INTRODUCTION
    • TABLE 62 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
  • 9.2 ONCOLOGY
    • 9.2.1 GROWING STUDIES ON CANCER THERAPEUTICS TO DRIVE MARKET GROWTH
    • TABLE 63 CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 64 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 65 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 66 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.3 CNS & MENTAL DISORDERS
    • 9.3.1 INCREASING CASES OF MENTAL DISORDERS TO DRIVE MARKET GROWTH
    • TABLE 67 CLINICAL TRIAL SUPPLIES MARKET FOR CNS & MENTAL DISORDERS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 68 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CNS & MENTAL DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 69 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CNS & MENTAL DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 70 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR CNS & MENTAL DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.4 CARDIOVASCULAR DISEASES
    • 9.4.1 GROWING INVESTMENTS BY PHARMACEUTICAL COMPANIES FOR CVD RESEARCH TO DRIVE GROWTH IN THIS MARKET SEGMENT
    • TABLE 71 CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 72 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 73 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 74 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.5 DIGESTIVE DISORDERS
    • 9.5.1 INCREASING R&D FOR THE DEVELOPMENT OF EFFECTIVE DRUGS TO DRIVE THE DEMAND FOR CLINICAL TRIAL SUPPLIES FOR THIS THERAPEUTIC AREA
    • TABLE 75 CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 76 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 77 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 78 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.6 INFECTIOUS DISEASES
    • 9.6.1 EMERGENCE OF NEW INFECTIONS SUCH AS EBOLA, ZIKA, AND COVID-19 HAS ACCELERATED THE EFFORTS TO DEVELOP NEW DRUGS-THIS WILL DRIVE THE DEMAND FOR CLINICAL TRIAL SUPPLIES
    • TABLE 79 CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 80 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 81 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 82 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.7 METABOLIC DISORDERS
    • 9.7.1 INCREASING PREVALENCE OF DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE MARKET GROWTH IN THE COMING YEARS
    • FIGURE 28 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM 2000 TO 2045 (IN MILLIONS)
    • TABLE 83 CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 84 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 85 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 86 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.8 BLOOD DISORDERS
    • 9.8.1 GROWTH IN THE NUMBER OF HEMOPHILIA PATIENTS TO BOOST THE PRODUCTION OF MACROMOLECULES AND RECOMBINANT FACTORS
    • TABLE 87 CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 88 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 89 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 90 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.9 IMMUNOLOGY
    • 9.9.1 CONTINUOUS GROWTH IN CLINICAL STUDIES FOR IMMUNE SYSTEM DISEASES TO FUEL THE NEED FOR PROCURING CLINICAL TRIAL SUPPLIES
    • TABLE 91 CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 92 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 93 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 94 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.10 OTHER THERAPEUTIC AREAS
    • TABLE 95 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 96 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 97 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 98 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION)

10 CLINICAL TRIAL SUPPLIES MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 99 CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.2.1 INCREASING R&D INVESTMENTS TO BOOST THE OUTSOURCING OF CLINICAL TRIAL SUPPLIES BY PHARMACEUTICAL AND BIOTECH COMPANIES
    • TABLE 100 CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 101 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 102 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 103 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 10.3 CONTRACT RESEARCH ORGANIZATIONS
    • 10.3.1 INCREASING OUTSOURCING OF CLINICAL TRIALS TO DRIVE THE ADOPTION OF CLINICAL TRIAL SUPPLIES AMONG CROS
    • TABLE 104 CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 105 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 106 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 107 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 10.4 MEDICAL DEVICE COMPANIES
    • 10.4.1 INCREASING NUMBER OF TRIALS OF MEDICAL DEVICES TO DRIVE MARKET GROWTH
    • TABLE 108 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 109 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 110 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 111 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)

11 CLINICAL TRIAL SUPPLIES MARKET, BY REGION

  • 11.1 INTRODUCTION
    • FIGURE 29 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHICAL SNAPSHOT
    • TABLE 112 CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 30 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT
    • TABLE 113 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 114 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 115 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 116 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 117 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 118 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.2.1 US
      • 11.2.1.1 Increasing R&D investments to drive market growth in the US
    • TABLE 119 US: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 120 US: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 121 US: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 122 US: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 123 US: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 Growing preference of pharmaceutical companies to conduct trials in Canada to favor market growth
    • TABLE 124 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 125 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 126 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 127 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 128 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 11.3 EUROPE
    • TABLE 129 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 130 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 131 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 132 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 133 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 134 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Growing number of sponsored trials to boost the demand for clinical trial supplies in Germany
    • TABLE 135 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 136 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 137 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 138 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 139 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.3.2 UK
      • 11.3.2.1 Government policies leading to costlier R&D and supply chain restrictions post Brexit to limit market growth to a certain extent
    • TABLE 140 UK: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 141 UK: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 142 UK: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 143 UK: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 144 UK: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.3.3 FRANCE
      • 11.3.3.1 Presence of leading pharmaceutical companies to support market growth in France
    • TABLE 145 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 146 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 147 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 148 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 149 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.3.4 ITALY
      • 11.3.4.1 Increasing number of drug approvals to drive the market for clinical trial supplies in Italy
    • TABLE 150 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 151 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 152 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 153 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 154 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.3.5 SPAIN
      • 11.3.5.1 Increasing biologics production to support market growth in Spain
    • TABLE 155 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 156 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 157 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 158 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 159 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.3.6 SWITZERLAND
      • 11.3.6.1 Growing R&D efforts to provide growth opportunities for the clinical trial supplies market in Switzerland
    • TABLE 160 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 161 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 162 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 163 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 164 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.3.7 REST OF EUROPE
    • TABLE 165 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 166 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 167 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 168 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 169 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • FIGURE 31 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT
    • TABLE 170 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 171 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 172 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 173 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 174 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 175 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.4.1 CHINA
      • 11.4.1.1 Favorable government regulations are boosting the market growth in China
    • TABLE 176 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 177 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 178 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 179 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 180 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.4.2 JAPAN
      • 11.4.2.1 Government initiatives for drug innovation to support market growth in Japan
    • TABLE 181 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 182 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 183 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 184 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 185 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Low manufacturing costs and a skilled workforce are factors attracting outsourcing and investment to India
    • TABLE 186 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 187 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 188 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 189 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 190 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.4.4 AUSTRALIA
      • 11.4.4.1 Australia has many research institutes conducting clinical trials-this is a key factor boosting the growth of the market
    • TABLE 191 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 192 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 193 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 194 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 195 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.4.5 SOUTH KOREA
      • 11.4.5.1 Government investments are a key contributor to market growth in South Korea
    • TABLE 196 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 197 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 198 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 199 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 200 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.4.6 SINGAPORE
      • 11.4.6.1 Presence of world-class infrastructure to drive market growth in Singapore
    • TABLE 201 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 202 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 203 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 204 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 205 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.4.7 REST OF ASIA PACIFIC
    • TABLE 206 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 207 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 208 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 209 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 210 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 11.5 ROW
    • TABLE 211 ROW: CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • 11.5.1 LATIN AMERICA
      • 11.5.1.1 Growing R&D expenditure in the pharmaceutical and biopharmaceutical sector to drive market growth in Latin America
    • TABLE 212 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 213 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 214 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 215 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 216 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 11.5.2 MIDDLE EAST & AFRICA
      • 11.5.2.1 Growing presence of pharmaceutical companies to drive market growth in the Middle East & Africa
    • TABLE 217 MIDDLE EAST & AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019-2026 (USD MILLION)
    • TABLE 218 MIDDLE EAST & AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 219 MIDDLE EAST & AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 220 MIDDLE EAST & AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 221 MIDDLE EAST & AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019-2026 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
    • FIGURE 32 CLINICAL TRIAL SUPPLIES MARKET: STRATEGIES ADOPTED
  • 12.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS
    • FIGURE 33 KEY PLAYERS IN THE CLINICAL TRIAL SUPPLIES MARKET
  • 12.4 MARKET SHARE ANALYSIS
    • FIGURE 34 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY KEY PLAYER, 2020
  • 12.5 COMPANY EVALUATION QUADRANT
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 35 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION QUADRANT, 2020
  • 12.6 CLINICAL TRIAL SUPPLIES MARKET: SME EVALUATION
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 STARTING BLOCKS
    • 12.6.3 RESPONSIVE COMPANIES
    • 12.6.4 DYNAMIC COMPANIES
    • FIGURE 36 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION QUADRANT FOR SMES, 2020
  • 12.7 COMPETITIVE BENCHMARKING
    • 12.7.1 COMPANY SERVICE FOOTPRINT (25 COMPANIES)
    • FIGURE 37 COMPANY PORTFOLIO FOOTPRINT: CLINICAL TRIAL SUPPLIES MARKET
    • TABLE 222 COMPANY REGION FOOTPRINT (25 COMPANIES)
    • TABLE 223 COMPANY SERVICE OFFERING FOOTPRINT (25 COMPANIES)
  • 12.8 GROWTH STRATEGIES ADOPTED BY MAJOR AND EMERGING PLAYERS
    • 12.8.1 CLINICAL TRIAL SUPPLIES MARKET: SERVICE LAUNCHES (JANUARY 2018 TO JUNE 2021)

13 COMPANY PROFILES

  • 13.1 MAJOR PLAYERS
  • (Business Overview, Services Offered, Recent Developments, and Right to Win)**
    • 13.1.1 CATALENT, INC.
    • TABLE 224 CATALENT, INC.: BUSINESS OVERVIEW
    • FIGURE 38 CATALENT, INC.: COMPANY SNAPSHOT (2020)
    • 13.1.2 PAREXEL
    • TABLE 225 PAREXEL: BUSINESS OVERVIEW
    • 13.1.3 BIOCAIR
    • TABLE 226 BIOCAIR: BUSINESS OVERVIEW
    • 13.1.4 ALMAC GROUP
    • TABLE 227 ALMAC GROUP: BUSINESS OVERVIEW
    • 13.1.5 THERMO FISHER SCIENTIFIC
    • TABLE 228 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 39 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
    • 13.1.6 PIRAMAL PHARMA SOLUTIONS
    • TABLE 229 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW
    • FIGURE 40 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2020)
    • 13.1.7 UDG HEALTHCARE
    • TABLE 230 UDG HEALTHCARE: BUSINESS OVERVIEW
    • FIGURE 41 UDG HEALTHCARE: COMPANY SNAPSHOT (2020)
    • 13.1.8 EUROFINS
    • TABLE 231 EUROFINS: BUSINESS OVERVIEW
    • FIGURE 42 EUROFINS: COMPANY SNAPSHOT (2020)
    • 13.1.9 MARKEN (A SUBSIDIARY OF UPS)
    • TABLE 232 UPS: BUSINESS OVERVIEW
    • FIGURE 43 UPS: COMPANY SNAPSHOT (2020)
    • 13.1.10 INFOSYS
    • TABLE 233 INFOSYS: BUSINESS OVERVIEW
    • FIGURE 44 INFOSYS: COMPANY SNAPSHOT (2020)
    • 13.1.11 PCI PHARMA SERVICES
    • TABLE 234 PCI PHARMA SERVICES: BUSINESS OVERVIEW
    • 13.1.12 PRA HEALTH SCIENCES
    • TABLE 235 PRA HEALTH SCIENCES: BUSINESS OVERVIEW
    • FIGURE 45 PRA HEALTH SCIENCES: COMPANY SNAPSHOT (2019)
    • 13.1.13 LIVEO RESEARCH (FORMERLY BILCARE RESEARCH)
    • TABLE 236 BILCARE RESEARCH: BUSINESS OVERVIEW
    • FIGURE 46 BILCARE RESEARCH: COMPANY SNAPSHOT (2020)
    • 13.1.14 CAPSUGEL (ACQUIRED BY LONZA GROUP)
    • TABLE 237 LONZA GROUP: BUSINESS OVERVIEW
    • FIGURE 47 LONZA GROUP: COMPANY SNAPSHOT (2020)
  • * Business Overview, Services Offered, Recent Developments, and Right to Win might not be captured in case of unlisted companies.
  • 13.2 OTHER PLAYERS
    • 13.2.1 SIRO CLINPHARM
    • 13.2.2 KLIFO
    • 13.2.3 CLINIGEN
    • 13.2.4 ANCILLARE
    • 13.2.5 N-SIDE
    • 13.2.6 ADALLEN PHARMA
    • 13.2.7 RUBICON RESEARCH
    • 13.2.8 DURBIN
    • 13.2.9 RECIPHARM
    • 13.2.10 SEVEILLAR CLINICAL SUPPLIES SERVICES
    • 13.2.11 MYONEX (FORMERLY MYODERM)

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 AVAILABLE CUSTOMIZATIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS